Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Madrigal Pharmaceuticals, Inc. (MDGL) had Receiveable Turnover of 2.54 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$287.27M |
|
$-114.19M |
|
$18.12M |
|
$269.15M |
|
$401.24M |
|
$-113.97M |
|
$-0.21M |
|
$-114.19M |
|
$-114.19M |
|
$-114.19M |
|
$-114.19M |
|
$-114.19M |
|
$-114.19M |
|
$-113.97M |
|
$-111.74M |
|
22.48M |
|
22.48M |
|
$-5.08 |
|
$-5.08 |
|
| Balance Sheet Financials | |
$1.35B |
|
$2.91M |
|
$15.78M |
|
$1.36B |
|
$391.41M |
|
$339.75M |
|
$345.32M |
|
$736.73M |
|
$625.73M |
|
$618.26M |
|
$625.73M |
|
22.70M |
|
| Cash Flow Statement Financials | |
$-56.09M |
|
$4.74M |
|
$247.03M |
|
$105.02M |
|
$300.69M |
|
$195.68M |
|
$72.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.44 |
|
-- |
|
-- |
|
0.35 |
|
0.54 |
|
93.69% |
|
-39.68% |
|
-39.68% |
|
-- |
|
-39.75% |
|
-39.75% |
|
$-56.95M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.26 |
|
|
Receiveable Turnover |
2.54 |
35.49 |
|
-18.25% |
|
-18.47% |
|
-8.38% |
|
-11.83% |
|
$27.56 |
|
$-2.53 |
|
$-2.49 |
|